Cytocast Digital Twin Platform

The CYTOCAST DIGITAL TWIN Platform™ is a high-performance computing platform developed by Cytocast that uses a particle-based stochastic simulation algorithm to replicate the complex molecular interactions of proteins within a virtual cell. By modeling protein complexation, decomplexation, and diffusion across cellular compartments and membranes, the platform delivers both qualitative and quantitative insights into the cellular complexome. It is designed for researchers and pharmaceutical companies seeking to evaluate drug safety and efficacy earlier in the development process, before committing to costly experiments or clinical trials.

Grounded in the principle that most biological functions are carried out by protein complexes, the platform predicts patient responses to treatments by simulating protein complex formation across multiple tissues — providing a foundation for personalized medicine. A central focus of the platform is off-target prediction and safety assessment, achieved by integrating diverse drug data from publicly available databases into a proteome-wide simulation pipeline and correlating perturbation-driven changes in protein complex abundance and structure with potential off-target effects and side effects.

Workflow: Input and Data Integration

• The workflow begins with the customer providing drug candidate information, typically supplied as a SMILES code.
• Cytocast integrates this input with partner data and a range of biological datasets to enrich the analysis.
• Drug target identification determines which proteins the drug candidate is expected to bind to.
• Proteomics data is incorporated to understand protein expression levels and interactions within the relevant cell type.
• Protein interaction networks are mapped to capture how proteins interact across different cellular environments.
• Complex formation pathways are studied to understand how protein complexes are assembled and how drug interactions perturb them.

Core AI-Powered Predictive Modeling Components

• Cytocast Off-Target Predictor (AI-powered) — Identifies unintended protein bindings that may lead to adverse effects, enabling early detection of off-target interactions.
• CYTOCAST DIGITAL TWIN Cell™ — Simulates protein complex perturbations, modeling how a drug affects cellular environments at the molecular level.
• Cytocast (Side) Effect Predictor (AI-powered) — Predicts potential side effects and broader drug effects, supporting comprehensive safety risk assessment.

Platform Output: The Cytocast Report

• The platform generates a comprehensive interactive report delivered directly to the customer.
• The report details predicted off-target interactions, identifying unintended binding sites across the proteome.
• It highlights protein complex perturbations, showing how the drug alters molecular networks within the cell.
• It includes predicted effects and side effects, flagging potential risks for further investigation and informing molecular design refinements.

By enabling early-stage evaluation of drug safety and efficacy through AI-powered predictive modeling and virtual cell simulation, the CYTOCAST DIGITAL TWIN Platform™ helps pharmaceutical companies and researchers accelerate drug discovery, reduce development risks, and refine molecular designs for safer and more effective therapeutics.